// App-Quantinova.ai

: Comparative effectiveness of abiraterone and enzalutamide in the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC): A retrospective cohort study in a large database of deeply curated EHR real-world data (RWD) from community oncology practices in the US.

Researchers

Presenter

  • Huijun An

Principal Investigators

  • Martin W. Schoen

  • Jennifer Rider

  • Anna E. Schorer

  • Jessica Ken

  • Li Chen

  • Amy Alabaster

  • Yanina Natanzon

Medical Centers

  • ConcertAI, Boston, MA

  • St. Louis Veterans Affairs Medical Center, St. Louis, MO

  • OncoLogic Consulting, LLC, Mendota Heights, MN

  • ConcertAI, Cambridge, MA

  • ConcertAI, King of Prussia, PA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Prostate specific antigen

  • Body mass index

Drug/Treatment

  • Enzalutamide

  • CB-7598

  • Androgen Tear

  • Techniclone TNT

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved